| Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer MM Awad, R Govindan, KN Balogh, DR Spigel, EB Garon, ME Bushway, ... Cancer Cell 40 (9), 1010-1026. e11, 2022 | 69 | 2022 |
| TLR-induced murine dendritic cell (DC) activation requires DC-intrinsic complement JH Sheen, MG Strainic, J Liu, W Zhang, Z Yi, ME Medof, PS Heeger The Journal of Immunology 199 (1), 278-291, 2017 | 58 | 2017 |
| Feasibility of real-time in vivo 89Zr-DFO-labeled CAR T-cell trafficking using PET imaging SH Lee, H Soh, JH Chung, EH Cho, SJ Lee, JM Ju, JH Sheen, H Kim, ... PLoS One 15 (1), e0223814, 2020 | 47 | 2020 |
| Effects of complement activation on allograft injury JH Sheen, PS Heeger Current opinion in organ transplantation 20 (4), 468-475, 2015 | 40 | 2015 |
| Abrogation of HLA surface expression using CRISPR/Cas9 genome editing: a step toward universal T cell therapy J Lee, JH Sheen, O Lim, Y Lee, J Ryu, D Shin, YY Kim, M Kim Scientific reports 10 (1), 17753, 2020 | 35 | 2020 |
| Structural and functional characterization of a monoclonal antibody blocking TIGIT BS Jeong, H Nam, J Lee, HY Park, KJ Cho, JH Sheen, E Song, M Oh, ... MAbs 14 (1), 2013750, 2022 | 10 | 2022 |
| Matrilysin (MMP-7) inhibition of BMP-7 induced renal tubular branching morphogenesis suggests a role in the pathogenesis of human renal dysplasia JK McGuire, S Harju-Baker, C Rims, JH Sheen, H Liapis Journal of Histochemistry & Cytochemistry 60 (3), 243-253, 2012 | 6 | 2012 |
| Direct and Indirect Chimeric Antigen Receptor T-Cell Imaging with PET/MRI in a Tumor Xenograft Model SY Kim, H Soh, JH Jung, EH Cho, H Kim, JM Ju, JH Sheen, SJ Lee, SJ Oh, ... Radiology 310 (2), e231406, 2024 | 1 | 2024 |
| A universal MHCII technology platform to characterize antigen-specific CD4+ T cells R Vyasamneni, V Kohler, B Karki, G Mahimkar, E Esaulova, J McGee, ... Cell Reports Methods 3 (1), 2023 | 1 | 2023 |
| Antibody to tigit and use thereof H Park, EJ Song, EH Lee, HI Yum, HM Nam, MK Kim, JW Lee, JH Sheen, ... US Patent App. 17/602,511, 2022 | 1 | 2022 |
| Toll-like receptor (TLR) 9-induced resistance to murine cardiac allograft tolerance is dependent upon C3a and C5a receptor (C3aR/C5aR) signaling J Sheen, P Heeger AMERICAN JOURNAL OF TRANSPLANTATION 16, 273-273, 2016 | 1 | 2016 |
| Effects of Toll like receptor (TLR) signaling on murine alloimmunity are modulated by immune cell derived complement J Sheen, P Heeger AMERICAN JOURNAL OF TRANSPLANTATION 15, 2015 | 1 | 2015 |
| Erratum for: Direct and Indirect Chimeric Antigen Receptor T-Cell Imaging with PET/MRI in a Tumor Xenograft Model SY Kim, H Soh, JH Jung, EH Cho, H Kim, JM Ju, JH Sheen, SJ Lee, SJ Oh, ... Radiology 310 (3), e249013, 2024 | | 2024 |
| 769 Interim clinical and translational data from NTC-001, a phase I study to evaluate the non-engineered neoantigen-specific T cell product BNT221 in patients with advanced or … JSW Borgers, D Lenkala, B McCarthy, V Kohler, S Hymson, E Jackson, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| MG1131, a novel TIGIT-targeting monoclonal antibody, enhances anti-tumor immune responses by modulating NK and T cell activity J Lee, M Kim, H Nam, JH Sheen, EJ Song, HI Yum, SJ Lim, HY Park Cancer Research 80 (16_Supplement), 2230-2230, 2020 | | 2020 |
| The first step toward the universal cell therapy: Simultaneous removal of HLAs (Human leukocyte antigens) using CRISPR-mediated quadruple genome editing in allogeneic T cells J Lee, M Kim, JH Sheen, J Ryu, YY Kim, O Lim JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019 | | 2019 |
| The Crosstalk Between TLR and DC-derived Complement Signaling in Heart Transplantation JHF Sheen Icahn School of Medicine at Mount Sinai, 2017 | | 2017 |
